Sun Pharma Acquires Checkpoint Therapeutics for $355 Million

CosmicTaco · 2025-03-10T10:17:23.332520+05:30

- Sun Pharmaceutical Industries Ltd announced the acquisition of Checkpoint Therapeutics, Inc., a Nasdaq-listed company specializing in immunotherapy and targeted oncology. - Checkpoint Therapeutics has FDA approval for UNLOXCYT (cosibelimab-ipdl), a treatment for adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC. - The acquisition includes an upfront cash payment of $4.10 per share and a contingent value right (CVR) for up to an additional $0.70 per share based on future milestones. - Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, emphasized the global reach and innovative portfolio in onco-dermatology therapy. - James Oliviero, President and CEO of Checkpoint, expressed pride in the team's dedication and excitement about the transaction, which aims to expand access to UNLOXCYT for patients in need. Source: [The Hindu](https://www.thehindu.com/business/Industry/sun-pharma-to-acquire-nasdaq-listed-oncology-firm-checkpoint-therapeutics-for-335-million/article69312007.ece), [News 18](https://www.news18.com/business/sun-pharma-to-acquire-nasdaq-listed-checkpoint-therapeutics-for-355-million-details-9255689.html), [The Economic Times](https://economictimes.indiatimes.com/markets/stocks/news/sun-pharma-shares-in-focus-as-co-announces-plan-to-acquire-checkpoint-therapeutics-for-355-million/articleshow/118829560.cms), [Moneycontrol](https://www.moneycontrol.com/news/business/markets/sun-pharma-to-acquire-nasdaq-listed-checkpoint-therapeutics-for-355-million-or-over-rs-3-000-crore-12960227.html)

Sun Pharmaceutical Industries Ltd announced the acquisition of Checkpoint Therapeutics, Inc., a Nasdaq-listed company specializing in immunotherapy and targeted oncology.
Checkpoint Therapeutics has FDA approval for UNLOXCYT (cosibelimab-ipdl), a treatment for adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC.
The acquisition includes an upfront cash payment of $4.10 per share and a contingent value right (CVR) for up to an additional $0.70 per share based on future milestones.
Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, emphasized the global reach and innovative portfolio in onco-dermatology therapy.
James Oliviero, President and CEO of Checkpoint, expressed pride in the team's dedication and excitement about the transaction, which aims to expand access to UNLOXCYT for patients in need.

Source: The Hindu, News 18, The Economic Times, Moneycontrol